What are some examples of biotech pitch decks?

Biotech pitch decks are specialized investor presentations designed to communicate a company’s scientific thesis, clinical pipeline, market opportunity, and funding needs to life science investors, venture capitalists, or strategic partners. Unlike a typical software startup deck, a strong biotech pitch deck must simultaneously educate a sophisticated audience on the underlying biology while making a compelling commercial case. The best examples share a common structure: they lead with a vivid patient problem, establish scientific credibility early, clearly define the mechanism of action, and tie everything back to a fundable milestone such as an IND filing, Phase 1 completion, or a partnership deal with a larger pharmaceutical company.

Early-stage biotech decks, such as those used by preclinical companies raising a seed or Series A round, typically run 15 to 20 slides and spend considerable real estate on the scientific differentiation section. A company developing a CRISPR-based gene editing therapy for sickle cell disease, for instance, would dedicate two to three slides to explaining why its guide RNA design outperforms existing approaches, supported by in vitro or mouse model efficacy data. Investors need to believe the science works before they will evaluate commercial potential, so skipping or compressing this section is one of the most common and costly mistakes founders make in early-stage biotech fundraising.

Later-stage decks, representing companies with Phase 2 or Phase 3 clinical data, shift the emphasis toward clinical outcomes, regulatory strategy, health economics, and the path to commercialization. A rare disease company with a confirmed orphan drug designation from the FDA, for example, would highlight the expedited approval pathway, the premium pricing environment, and the relatively small but well-defined patient population as a de-risking story for investors. At this stage, the competitive landscape slide becomes critical — investors want to see how your asset compares head-to-head with current standard of care and any rival therapies in late-stage development, ideally using a feature matrix with clear differentiation markers like dosing frequency, safety profile, or route of administration.

• A slide dedicated to the unmet medical need should quantify the patient population using epidemiology data, such as ‘400,000 diagnosed patients in the US annually with fewer than three approved therapies,’ to make the opportunity concrete and defensible to investors.
• The mechanism of action slide works best when it uses a simple visual diagram showing exactly where in the disease pathway your molecule or therapy intervenes, rather than relying on dense scientific text that loses non-specialist investors.
• A clinical or preclinical data slide should present key efficacy and safety figures in a clean graph format, including error bars and sample sizes, since omitting statistical context raises red flags for scientifically literate life science investors.
• The IP and defensibility slide should specify patent expiration dates, the number of issued versus pending patents, and whether freedom-to-operate analysis has been completed, since these details directly affect valuation conversations.
• A milestone and use of proceeds slide should map each funding tranche to a specific clinical or regulatory milestone, such as ‘Series A capital funds us to IND submission in Q3 2025 and Phase 1 enrollment by Q1 2026,’ giving investors a clear timeline to value inflection.
• The team slide in biotech carries more weight than in most industries and should highlight advisors with specific domain expertise, prior drug approval experience, and key opinion leader relationships relevant to your therapeutic area.
• A partnering or exit slide should reference comparable acquisitions in your space with deal values and timing, helping investors visualize a realistic liquidity event within their typical seven to ten year fund horizon.

When building or refining your own biotech pitch deck, the most actionable next step is to study publicly available decks from companies in your therapeutic area that have successfully closed rounds, many of which are shared on investor relations pages after a company goes public. Pay close attention to how they sequence the science-to-business narrative and where they place their strongest data. Keep in mind that this pitch deck framework is less applicable if you are pitching a biotech tools or services company, such as a CRO or lab automation firm, since those businesses follow a more conventional revenue-model-forward structure closer to a traditional SaaS or services pitch.